COLL - Collegium Pharmaceutical, Inc.
11.35 0.00 (0.00%)
After hours: 4:05PM EDT
| Previous Close | 11.15 |
| Open | 11.08 |
| Bid | 11.22 x 800 |
| Ask | 11.38 x 4000 |
| Day's Range | 10.98 - 11.42 |
| 52 Week Range | 10.55 - 28.91 |
| Volume | 416,678 |
| Avg. Volume | 365,404 |
| Market Cap | 378.939M |
| Beta (3Y Monthly) | 0.62 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.91 |
| Earnings Date | Mar 7, 2018 - Mar 12, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 28.14 |
- GlobeNewswire•21 days ago
Collegium to Present at Upcoming Investor Conferences
STOUGHTON, Mass., May 29, 2019 -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain.
- Thomson Reuters StreetEvents•last month
Edited Transcript of COLL earnings conference call or presentation 8-May-19 8:30pm GMT
Q1 2019 Collegium Pharmaceutical Inc Earnings Call
Motley Fool•last monthCollegium Pharmaceutical, Inc. (COLL) Q1 2019 Earnings Call Transcript
COLL earnings call for the period ending March 31, 2019.
- Insider Monkey•last month
Were Hedge Funds Right About Dumping Collegium Pharmaceutical Inc (COLL) ?
At Insider Monkey, we pore over the filings of nearly 750 top investment firms every quarter, a process we have now completed for the latest reporting period. The data we've gathered as a result gives us access to a wealth of collective knowledge based on these firms' portfolio holdings as of December 31. In this […]
Motley Fool•last monthAssertio Therapeutics, Inc (ASRT) Q1 2019 Earnings Call Transcript
ASRT earnings call for the period ending March 31, 2019.
- Zacks•last month
Collegium Pharmaceutical (COLL) Reports Q1 Loss, Tops Revenue Estimates
Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of 83.33% and 6.29%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•last month
Collegium Pharmaceutical: 1Q Earnings Snapshot
The Stoughton, Massachusetts-based company said it had a loss of 29 cents per share. Losses, adjusted for stock option expense and non-recurring costs, were 5 cents per share. The results exceeded Wall ...
- GlobeNewswire•last month
Collegium Reports First Quarter 2019 Financial Results
Xtampza® ER Net Product Revenues of $25.1 million in the First Quarter of 2019, a 59% increase over the First Quarter of 2018 and a 36% increase on a Consecutive-Quarter.
- Zacks•last month
Assertio Therapeutics (ASRT) to Post Q1 Earnings: What's Up?
During Assertio Therapeutics' (ASRT) Q1 conference call, investor focus will be on the company's progress with its neurology franchise and the NDA filing for cosyntropin.
- Motley Fool•last month
2 Big Biotech Stock Upgrades: Can They Reach These Targets?
Investment-bank analysts think these drugmakers are worth a lot more than the stock market does at the moment.
- Zacks•2 months ago
Collegium Pharmaceutical (COLL) Expected to Beat Earnings Estimates: Should You Buy?
Collegium Pharmaceutical (COLL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- GlobeNewswire•2 months ago
Collegium to Participate in Upcoming Investor Conferences
STOUGHTON, Mass., April 30, 2019 -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain.
- GlobeNewswire•2 months ago
Collegium to Host Conference Call to Discuss First Quarter 2019 Financial Results and Provide Corporate Update
STOUGHTON, Mass., April 24, 2019 -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced today that the Company will host a conference call and live audio webcast on.
- GlobeNewswire•3 months ago
Collegium Appoints Richard Malamut, M.D., as Chief Medical Officer
Collegium Pharmaceutical, Inc. (COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced the appointment of Richard Malamut, M.D., as the company’s first Chief Medical Officer, effective April 1, 2019. In this newly created role, Dr. Malamut will lead Collegium’s Clinical, Medical Affairs, Regulatory and Scientific Affairs functions. “We are excited to have Rick join the Collegium leadership team.
- Simply Wall St.•3 months ago
Read This Before Buying Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Shares
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. The flip sid...
- Zacks•3 months ago
Collegium Pharmaceutical (COLL) Upgraded to Buy: What Does It Mean for the Stock?
Collegium Pharmaceutical (COLL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).
- Motley Fool•3 months ago
Assertio Therapeutics, Inc (ASRT) Q4 2018 Earnings Conference Call Transcript
ASRT earnings call for the period ending December 31, 2018.
- Thomson Reuters StreetEvents•4 months ago
Edited Transcript of COLL earnings conference call or presentation 27-Feb-19 9:30pm GMT
Q4 2018 Collegium Pharmaceutical Inc Earnings Call
Motley Fool•4 months agoCollegium Pharmaceutical Inc (COLL) Q4 2018 Earnings Conference Call Transcript
COLL earnings call for the period ending December 31, 2018.
- GlobeNewswire•4 months ago
Collegium Reports Fourth-Quarter and Full-Year 2018 Financial Results
Xtampza® ER Prescriptions Grew 233% in 2018Net Revenue Increased to $73.4 Million for Fourth Quarter 2018 and $280.4 Million for the Full YearCash and Cash Equivalents were.
- Zacks•4 months ago
Collegium Pharmaceutical (COLL) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Collegium Pharmaceutical (COLL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks•4 months ago
ASRT or COLL: Which Is the Better Value Stock Right Now?
ASRT vs. COLL: Which Stock Is the Better Value Option?
- GlobeNewswire•4 months ago
Collegium to Host Conference Call to Discuss Fourth Quarter 2018 Financial Results and Provide Corporate Update
STOUGHTON, Mass., Feb. 13, 2019 -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced today that the Company will host a conference call and live audio webcast on.
- Simply Wall St.•4 months ago
Breakeven On The Horizon For Collegium Pharmaceutical, Inc. (NASDAQ:COLL)
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL): Collegium Pharmaceutical, Inc.,Read More...
